Desarrollo y caracterización de nanopartículas de gantrez an 119 con ciclosporina a para administración oral. Comportamiento in vivo
- Autores: Marisin Pecchio González
- Directores de la Tesis: María del Carmen Dios Vieitez (dir. tes.), María Jesús Renedo Omaechevarría (codir. tes.)
- Lectura: En la Universidad de Navarra ( España ) en 2010
- Idioma: español
- Tribunal Calificador de la Tesis: Juan Manuel Irache Garreta (presid.), Azucena Aldaz Pastor (secret.), Elvira Escribano Ferrer (voc.), María José García Celma (voc.), Begoña Calvo Hernáez (voc.)
- Materias:
- Texto completo no disponible (Saber más ...)
- Resumen
Cyclosporine A has been widely used because it is a potent immuno-suppressive agent, however it present low bioavailability and many problems to be formulated. Thus, we have developed 13 new formulations for this drug in Gantrez® AN 119 nanoparticles, which one expects to be alternative to those currently available commercial. Four formulations were optimized, those had the most interesting properties, and then we selected three to study their in vivo behaviour in rat. Our results show those three formulations could be alternatives to the commercial formulation Sandimmun Neoral® for oral administration of cyclosporine A. In view of the result, the formulation C(17.5) is probably the best because when cyclosporine is administered in this formulation we has been found drug bioavailability in magnitude increase 21.43% that when the drug is administrated in the oral formulation Sandimmun Neoral®, on the other hand when the drug is administrated in formulations E(12.5) and G(15) cyclosporine bioavailability is similar to the one which presents commercial formulation. Finally, the time needed to reach maximum blood concentration for three formulations developed is greater than the one corresponding to the commercial formulation, resulting in sustained drug levels.
